Interim report January – March 2023
First quarter in brief · Net sales amounted to 16,1 million SEK (9,9), which means a sales growth of 63 percent. ·Operating profit amounted to -2 million SEK (-3,6), corresponding to an operating margin of -13 percent (-37). ·Net profit for the period amounted to -2,2 million SEK (-3,5). ·Earnings per share amounted to -0.05 SEK (-0.08). Significant events during the first quarter During the first quarter SyMRI received regulatory approval in Singapore, UK and Canada. Significant events after the first quarter Nothing to report.CEO comments